Generalized lipodystrophy
Methodology & AI Transparency ⓘ
Generalized lipodystrophy Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Clinical triage of Generalized lipodystrophy (E88.12) in Weight & Metabolism relies on fasting cardiometabolic panels [Generalized lipodystrophy E88.12], guiding step-wise therapeutic adjustments toward ALT & Fasting in Generalized lipodystrophy (E88.12: Triglycerides) (ALT < 25 U/L; TG < 100 mg/dL (E88.12)).
- 2 Real-world patient consensus: Diagnostic registry E88.12: Generalized lipodystrophy is managed within Weight & Metabolism.
- 3 Typical cash cost range: Primary evaluation for Generalized lipodystrophy incorporates fasting cardiometabolic panels [Generalized lipodystrophy E88.12] and symptom diary review.
- 4 Top reported side effects / signs: Longitudinal Generalized lipodystrophy monitoring tracks HOMA-IR Insulin Resistance in Generalized lipodystrophy (E88.12: Index) toward < 1.4 (E88.12).
Ask our AI Specialists anything about Generalized lipodystrophy
What Is Generalized lipodystrophy?
Clinical triage of Generalized lipodystrophy (E88.12) in Weight & Metabolism relies on fasting cardiometabolic panels [Generalized lipodystrophy E88.12], guiding step-wise therapeutic adjustments toward ALT & Fasting in Generalized lipodystrophy (E88.12: Triglycerides) (ALT < 25 U/L; TG < 100 mg/dL (E88.12)).
Pathophysiology, Underlying Causes & Clinical Presentation
Mechanistic hallmarks of Generalized lipodystrophy (E88.12) center on TNF-alpha) [Generalized lipodystrophy E88.12]. targeted weight & metabolism interventions aim to normalize HOMA-IR Insulin Resistance in Generalized lipodystrophy (E88.12: Index).
Common Symptoms & Clinical Signs
- • Presentation of Generalized lipodystrophy (E88.12): daytime sluggishness or in Generalized lipodystrophy (E88.12: loud snoring linked)
- • Secondary Generalized lipodystrophy clinical sign: central abdominal visceral in Generalized lipodystrophy (E88.12: fat accumulation resistant)
- • Symptom flares in Generalized lipodystrophy correlating with HOMA-IR Insulin Resistance in Generalized lipodystrophy (E88.12: Index) deviation outside < 1.4 (E88.12)
- • Functional weight & metabolism impact requiring fasting cardiometabolic panels [Generalized lipodystrophy E88.12] evaluation (E88.12)
Generalized lipodystrophy Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | E88.12 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Weight Management & Metabolic Syndrome | NLM Clinical Tables |
| Diagnostic / Lab Marker: HOMA-IR Insulin Resistance in Generalized lipodystrophy (E88.12: Index) | < 1.4 (E88.12) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: ALT & Fasting in Generalized lipodystrophy (E88.12: Triglycerides) | ALT < 25 U/L; TG < 100 mg/dL (E88.12) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: DEXA Visceral Adipose in Generalized lipodystrophy (E88.12: Tissue (VAT)) | < 1.0 lb (< 100 cm2) (E88.12) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Generalized lipodystrophy
| Medication | Pharmacologic Class | Patient Worth-It | CMS NADAC / Unit | Typical Lowest Cash |
|---|---|---|---|---|
| Alprazolam Xanax • RxCUI 197321 | Benzodiazepine | 90% | $0.0250 | $ 9.51 /mo |
| Fosphenytoin Sodium Cerebyx • RxCUI 1670195 | Anti-epileptic Agent | 94% | $0.7800 | $ 40.09 /mo |
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Generalized lipodystrophy)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Coadministered Cagrilintide and Semaglutide in Adults with Overweight or: What a 3,417-Participant Study Found Cagrilintide-semaglutide provided significant and clinically relevant body-weight reductions in adults with overweight or obesity, as compared with placebo. The New England journal of medicine • 2025-08-14 • Phase III Randomized Trial | N = 3,417 | 96/100 | PMID 40544433 ↗ |
| New Insights on Tirzepatide Efficacy and Tolerability According to Early Weight Response: A Post: What a 1,775-Participant Study Found In this post hoc analysis of the SURMOUNT-1 and SURMOUNT-2 trials, tirzepatide-treated participants with obesity or overweight in both ER and non-ER groups achieved clinically meaningful weight reduction and improvements in... Diabetes, obesity & metabolism • 2026-09-15 • Phase III Randomized Trial | N = 1,775 | 96/100 | PMID 42348366 ↗ |
| New Insights on Sertraline treatment for generalized anxiety: a randomized, gold-standard blind,: What a 326-Participant Study Found Despite the relatively small between-group differences, study findings suggest a role for sertraline in the acute treatment of GAD. The Journal of clinical psychiatry • 2006-06-15 • Randomized Controlled Trial | N = 326 | 93/100 | PMID 16848646 ↗ |
| New Insights on Benefits and safety of semaglutide compared with liraglutide and placebo for: What a 957-Participant Study Found In combination with dietary and physical activity counselling, semaglutide was well tolerated over 52 weeks and showed clinically relevant weight loss compared with placebo at all doses. Lancet (London, England) • 2018-08-25 • Randomized Controlled Trial | N = 957 | 93/100 | PMID 30122305 ↗ |
| New Insights on Benefits and safety of etifoxine versus alprazolam in generalized anxiety with: What a 260-Participant Study Found Treatment-emergent AEs were mild and observed in 10% and 7.7% of patients in the Etifoxine and Alprazolam groups, respectively. Journal of anxiety disorders • 2026-04-15 • Phase III Randomized Trial | N = 260 | 93/100 | PMID 41763071 ↗ |
Generalized lipodystrophy Patient Community & “People Like Me” Threads
Filter Generalized lipodystrophy community threads and patient logs by age, biological sex, dosage, and treatment duration.